Market closedNon-fractional
Tourmaline Bio/TRML
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Tourmaline Bio
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Ticker
TRML
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
58
Website
www.tourmalinebio.com
Tourmaline Bio Metrics
BasicAdvanced
$439M
Market cap
-
P/E ratio
-$4.55
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$439M
Financial strength
Current ratio
62.171
Quick ratio
60.712
Long term debt to equity
0.043
Total debt to equity
0.106
Management effectiveness
Return on assets (TTM)
-18.97%
Return on equity (TTM)
-27.05%
Valuation
Price to book
1.22
Price to tangible book (TTM)
1.22
Price to free cash flow (TTM)
-4.598
Growth
Earnings per share change (TTM)
83.57%
What the Analysts think about Tourmaline Bio
Analyst Ratings
Majority rating from 6 analysts.
Tourmaline Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$13M
-733.33%
Profit margin
0.00%
NaN%
Tourmaline Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 22
Q1 23
Q4 23
Q1 24
Q2 24
Actual
-$4.40
-$5.40
-$0.81
-$0.55
-
Expected
-$4.90
-$3.50
-$0.79
-$0.67
-$0.71
Surprise
-10.20%
54.29%
2.53%
-17.71%
-
Tourmaline Bio News
AllArticlesVideos
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
GlobeNewsWire·4 weeks ago
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tourmaline Bio stock?
Tourmaline Bio (TRML) has a market cap of $439M as of July 27, 2024.
What is the P/E ratio for Tourmaline Bio stock?
The price to earnings (P/E) ratio for Tourmaline Bio (TRML) stock is 0 as of July 27, 2024.
Does Tourmaline Bio stock pay dividends?
No, Tourmaline Bio (TRML) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Tourmaline Bio dividend payment date?
Tourmaline Bio (TRML) stock does not pay dividends to its shareholders.
What is the beta indicator for Tourmaline Bio?
Tourmaline Bio (TRML) does not currently have a Beta indicator.
Buy or sell Tourmaline Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.